Parabilis Medicines, Inc. SEC Filings

Parabilis Medicines’ major Soleus-affiliated holders increased their indirect stake through both conversion and open-market buying. On June 11, 2026, Soleus investment funds converted 527,070 shares of Series F Preferred Stock into common stock at $9.48 per share in an automatic conversion tied to the company’s initial public offering.

The same day, Soleus-related entities purchased an additional 500,000 common shares in open-market transactions at $20.00 per share, bringing their reported indirect common stock holdings to 1,027,000 shares for Section 16 reporting purposes.

Parabilis Medicines, Inc. filed an initial ownership report showing that investment entities associated with Soleus Capital hold Series F Preferred Stock that is convertible into 527,070 shares of Common Stock at a conversion price of $9.48 per share. The securities are owned directly by Soleus Private Equity Fund III, L.P., with various Soleus general partner and management entities, and Guy Levy, identified as indirect 10% owners. The filing notes that the preferred stock is convertible at any time at the holder’s election and has no expiration date, and the reporting persons disclaim beneficial ownership beyond their pecuniary interests.

RA Capital Management and affiliated funds report a 23.8% beneficial stake in Parabilis Medicines, Inc. common stock. They disclose beneficial ownership of 28,933,371 shares of voting common stock, based on 121,589,570 shares outstanding as of June 11, 2026.

The position comes from pre-IPO preferred stock investments with an aggregate purchase price of $73,499,989 that converted into common shares at the IPO, plus additional IPO purchases totaling 21,188,750 common shares at $20.00 per share for $423,775,000. RA Capital acts as investment adviser and holds sole voting and dispositive power delegated by its funds.

RA Capital states the shares are held for investment purposes without a current plan to change control, though it may buy or sell securities over time. The funds are subject to 180-day IPO lock-up agreements and benefit from investor registration rights, including demand, Form S-3, and piggyback registration rights for future resales.

Parabilis Medicines director Alan Sebulsky reported indirect open-market purchases of Parabilis Medicines, Inc. common stock through Apothecary Capital LLC. Across three transactions on June 12 and June 15, Apothecary Capital bought a total of 17,500 shares at weighted average prices reported as $27.6696, $25.9978 and $27.0963 per share. Following the most recent transaction, Apothecary Capital holds 30,000 shares. Footnotes state Sebulsky is the managing member of Apothecary Capital and may share voting and investment power but disclaims beneficial ownership beyond any pecuniary interest.

Parabilis Medicines, Inc. disclosed that investment vehicles managed by RA Capital made substantial purchases and conversions into its Voting Common Stock. On June 11, 2026, RA Capital–related funds completed open‑market purchases totaling 21,188,750 shares of Voting Common Stock at $20.00 per share, held indirectly through the funds. On the same date, Series E and Series F Preferred Stock automatically converted into additional Voting Common Stock immediately prior to the closing of the IPO, with Series E converting at a 1 to 0.6524 ratio and Series F at a 1 to 0.6498 ratio, without payment of consideration. The RA Capital adviser and related entities disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.

Parabilis Medicines director Edward M. Fitzgerald reported a series of non-cash conversions of preferred stock into common shares. On June 11, 2026, he converted Series B, C and F Preferred Stock into Common Stock, acquiring 5,539, 3,878 and 5,271 common shares, respectively, at $0.00 per share.

These preferred shares automatically converted into common immediately prior to the closing of the company’s initial public offering on June 9, 2026, as described in the footnotes. No shares were sold; all Form 4 transactions are coded as conversions of derivative securities. Following these transactions, Fitzgerald directly holds 14,688 shares of Common Stock.

Parabilis Medicines, Inc. director-associated entity Apothecary Capital LLC made an open-market purchase of 12,500 shares of common stock at $20.00 per share on June 11, 2026. The shares are held indirectly, with Alan Sebulsky disclaiming beneficial ownership except for any pecuniary interest.

Parabilis Medicines director Alexis Borisy converted preferred stock into common shares tied to the company’s IPO. On June 11, 2026, 162,221 shares of Series F Preferred Stock were converted into 105,414 shares of Common Stock, leaving him with 105,414 common shares directly owned. According to the terms, each preferred share converted at a 1 to 0.6498 rate and automatically converted into common shares immediately before the closing of the initial public offering on June 9, 2026. This was a non-cash derivative conversion, not an open‑market purchase or sale.

Parabilis Medicines, Inc. reported that investment funds managed by Deerfield converted multiple series of preferred stock into voting common stock in connection with the company’s initial public offering. The Form 4 shows Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund III, L.P. acquiring an aggregate of 2,042,004 shares of voting common stock through automatic conversions coded as “C” transactions, all at a stated price of $0.00 per share. After these conversions, the preferred stock positions reported for Series A, B, C and D show zero remaining shares, indicating full conversion into common. The filing states that the Deerfield-affiliated reporting persons disclaim beneficial ownership beyond any indirect pecuniary interest.